Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, Mantle-Cell 2Lymphoma 2Leukemia 2Recurrence 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, B-Cell 1

Interventions

Rituximab 78Cyclophosphamide 76fludarabine phosphate 45Peripheral Blood Stem Cell Transplantation 41Mycophenolic Acid 39Tacrolimus 35Whole-Body Irradiation 33Radiotherapy 29Busulfan 29Cyclosporine 27Antilymphocyte Serum 27Etoposide 25Filgrastim 24Methotrexate 22Melphalan 22Lenalidomide 15Cytarabine 15Cord Blood Stem Cell Transplantation 14fludarabine 13Methylprednisolone 13Bortezomib 13orelabrutinib 12Dexamethasone 12sargramostim 11obinutuzumab 11Sirolimus 9Carmustine 9venetoclax 8Vincristine 8Prednisone 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, B-Cell, Marginal Zone × Chlorambucil × Clear all
NCT01808599 2026-01-15

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

International Extranodal Lymphoma Study Group (IELSG)

Phase 2 Active not recruiting
112 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡